LENG9 Inhibitors
LENG9 inhibitors pertain to a category of chemical compounds that indirectly affect the activity of LENG9 by interacting with signaling pathways or cellular processes that LENG9 is involved in. These inhibitors do not target LENG9 directly but can alter its functional state by modulating the activity of proteins and enzymes that interact with or regulate LENG9.
Staurosporine is known for its potent inhibition of protein kinases such as PKC. This inhibition can have a cascading effect on various signaling pathways within the cell. If LENG9's activity is modulated by a kinase that Staurosporine inhibits, then the functional state of LENG9 could be affected as a consequence of this inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, known to suppress the activity of protein kinase C (PKC), which can lead to the dephosphorylation of various substrates that may be crucial for the stability and function of LENG9. Its inhibition of PKC could, therefore, reduce LENG9's functional activity if phosphorylation by PKC is necessary for LENG9's stability or activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), which play a pivotal role in the PI3K/AKT signaling pathway responsible for cell proliferation and survival. Inhibition of PI3K can lead to a decrease in AKT phosphorylation, which could indirectly inhibit LENG9 if LENG9 is a downstream effector in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin), which is central to the mTOR signaling pathway involved in cell growth and proliferation. Inhibition of mTOR can result in the downregulation of its downstream effectors, which may include LENG9 if it is part of the mTOR signaling network. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK1/2, enzymes within the MAPK/ERK pathway. Inhibition of MEK results in decreased activation of ERK, which can lead to reduced phosphorylation of ERK's substrates. If LENG9 is regulated by ERK-mediated phosphorylation, PD98059 could decrease LENG9 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of both MEK1 and MEK2, which are upstream activators of ERK in the MAPK pathway. By preventing the activation of ERK, U0126 may indirectly inhibit LENG9 function if LENG9 is a downstream target of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 targets p38 MAP kinase within the MAPK pathway, particularly in response to stress signals. Inhibition of p38 MAP kinase can lead to a decrease in activity of proteins involved in stress responses, including potentially LENG9 if it is modulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the stress-activated MAPK pathways. Inhibition of JNK signaling could lead to reduced transcriptional activation of stress response genes, which may include LENG9 if it is a JNK-regulated protein. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases, which are involved in various signaling pathways that control cell proliferation and differentiation. Inhibition of Src kinases by PP2 could reduce LENG9 activity if LENG9 is affected by Src signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, leading to a reduction in AKT signaling. Through this inhibition, it can reduce the activity of downstream proteins within the PI3K/AKT pathway, potentially including LENG9 if it is a downstream effector. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent antagonist of the Gs alpha subunit of G-proteins. By inhibiting Gs alpha, it can reduce adenylate cyclase activity, leading to lower levels of cAMP and thereby decreasing PKA activity. This reduction could lead to decreased phosphorylation and activity of LENG9 if it is regulated by the cAMP/PKA signaling axis. | ||||||